Patrisa Gonzalez
Family · Columbia, SCNPI 1881234631
Payments from drug & device makers
Across 268 payments — averaging $19.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$907
- Novartis$619
- Pfizer$436
- Merck$422
- AstraZeneca$402
- Boston Scientific$368
- plus $2K from 15 others
What the payments were for
- Food & beverage$5,162100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 42 | $907 |
| Novartis | 45 | $619 |
| Pfizer | 22 | $436 |
| Merck | 23 | $422 |
| AstraZeneca | 23 | $402 |
| Boston Scientific | 14 | $368 |
| Boehringer Ingelheim | 18 | $324 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $279 |
| Actelion Pharmaceuticals US, Inc. | 13 | $236 |
| Bayer | 13 | $223 |
| Cvrx, Inc. | 5 | $195 |
| Bridgebio Pharma, Inc. | 5 | $143 |
| Scpharmaceuticals Inc. | 7 | $122 |
| Johnson & Johnson | 7 | $118 |
| Novo Nordisk | 4 | $94 |
| Daiichi Sankyo Inc. | 4 | $76 |
| Impulse Dynamics (USA) Inc. | 5 | $67 |
| Recor Medical Inc | 2 | $50 |
| E.r. Squibb & Sons, L.L.C. | 2 | $36 |
| Nuwellis, Inc. | 2 | $35 |
| Vifor Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,162 in reported general payments places this provider in the 90th percentile of 3,248 family providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 12 | $11,924 |
| EntrestoSacubitril/Valsartan | 13 | $9,479 |
| EliquisApixaban | 12 | $7,536 |
| FarxigaDapagliflozin Propanediol | 11 | $6,770 |
| Bumetanide | 15 | $533 |
| Atorvastatin Calcium | 30 | $337 |
| Metoprolol Succinate | 15 | $121 |
| Furosemide | 12 | $21 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $324 | $11,92412 claims |
| NovartisEntresto | $619 | $9,47913 claims |
| PfizerEliquis | $436 | $7,53612 claims |
| AstraZenecaFarxiga | $402 | $6,77011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,248 family providers in South Carolina.
Other family in Columbia
- Mary WilliamsColumbia$67K
- Devon DriverColumbia$21K
- Amanda CharltonColumbia$15K
- Katherine ColemanColumbia$15K
- Melissa RedmondColumbia$13K
- Andrew FieldsColumbia$12K
- Jodi MyersColumbia$12K
- Alaina McClerklinColumbia$11K
- Coty CampbellColumbia$11K
- Patricia DaileyColumbia$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.